WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004009083) ANTITUMOR COMPOUND AND THERAPEUTIC USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/009083    International Application No.:    PCT/EP2003/007963
Publication Date: 29.01.2004 International Filing Date: 22.07.2003
IPC:
A61K 31/403 (2006.01)
Applicants: CELL THERAPEUTICS EUROPE S.R.L. [IT/IT]; Via Ariosto, 23, I-20091 Bresso (IT) (For All Designated States Except US).
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI [IT/IT]; Via Venezian, 1, I-20133 Milano (IT) (For All Designated States Except US).
LANZI, Cinzia [IT/IT]; (IT) (For US Only).
CASSINELLI, Giuliana [IT/IT]; (IT) (For US Only).
CUCCURU, Giuditta [IT/IT]; (IT) (For US Only).
PIEROTTI, Marco, Alessandro [IT/IT]; (IT) (For US Only).
ZUNINO, Franco [IT/IT]; (IT) (For US Only).
MENTA, Ernesto [IT/IT]; (IT) (For US Only)
Inventors: LANZI, Cinzia; (IT).
CASSINELLI, Giuliana; (IT).
CUCCURU, Giuditta; (IT).
PIEROTTI, Marco, Alessandro; (IT).
ZUNINO, Franco; (IT).
MENTA, Ernesto; (IT)
Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Plinio, 63, I-20129 Milano (IT)
Priority Data:
MI02A001620 23.07.2002 IT
Title (EN) ANTITUMOR COMPOUND AND THERAPEUTIC USES THEREOF
(FR) COMPOSE ANTITUMORAL ET SES UTILISATIONS THERAPEUTIQUES
Abstract: front page image
(EN)The use of an arylidene 2-indolinone derivative for treating tumors involving Met, PDGF-R, FGF-RI, FGF-R3 and Kit tyrosine kinases, or the oncoproteins of Ret family is disclosed. The invention also provides pharmaceutical compositions comprising laid arylidene 2-indolinone derivative as well as a kit comprising, in separate containers, said derivative and an anti-cancer or anti-tumor agent.
(FR)L'invention concerne l'utilisation d'un dérivé arylidène 2-indolinone pour le traitement de tumeurs impliquant des Met, des PDGF-R, des FGF-RI, des FGF-R3 et des Kit tyrosine kinases, ou les oncoprotéines de la famille Ret. L'invention concerne également des compositions pharmaceutiques comprenant ledit dérivé arylidène 2-indolinone, ainsi qu'une trousse comprenant, dans des contenants séparés, ledit dérivé et un agent anticancéreux ou antitumoral.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)